Immune checkpoint inhibitors (ICIs), including anti-CTLA-4, anti-PD-1, and anti-PD-L1 agents, have revolutionized cancer therapy by enhancing T-cell–mediated antitumor responses and significantly improving survival across multiple malignancies. Despite these advances, ICIs are associated with immune-related adverse eve...
C. S. Matichecchia, F. Fanizzi, A. Zilli et al.· Cancers· 0 citations
By combining structured clinical variables and multimodal imaging data, the AI-HOPE Lung Cancer study aims to support refined risk stratification and treatment personalization, ultimately facilitating the responsible integration of AI into routine thoracic oncology practice.
F. Ogliari, M. Ferrara, J. Huijs et al.· ESMO real world data and dig...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.